Impact of Aldosterone Synthase Gene C-344T Polymorphism on IgA Nephropathy

Figures & data

Figure 1. Genotype distribution of aldosterone synthase (CYP11B2) gene C-344T polymorphism in n = 100 healthy volunteers and in n = 143 patients with biopsy-proven IgA nephropathy.

Note: ns, not significant.

Table 1. Clinical and laboratory parameters at the time of renal biopsy (mean ± SD) in n = 143 patients with IgA nephropathy according to the aldosterone synthase gene C-344T genotype

Aldosterone synthase C-344T polymorphism
	CC/CT	TT	Significance
Number (n)	95	48
Follow-up (years)	7.1 ± 6	7.2 ± 7	ns
Male/female ratio	3.3	2.0	ns
Age (years)	37.0 ± 14	38.7 ± 15	ns
Creatinine (mg/dL)	2.1 ± 1.4	2.2 ± 1.3	ns
Proteinuria (g/24 h)	3.6 ± 2.9	4.2 ± 2.8	ns
Hypertension (%)	84.8	91.7	ns
MAP (mmHg)	111.9 ± 13	111.0 ± 13	ns
Antihypertensives (n)	2.2 ± 1.3	2.1 ± 1.2	ns
ACE/AT1R inhibition (%)	62.8	61.9	ns
Sclerosed glomeruli (%)	29.3 ± 26.5	21.7 ± 25.2	ns
Tubulointerstitial fibrosis (%)	31.3 ± 23.5	34.2 ± 24.3	ns
Arteriosclerosis (+/+++)	1.37 ± 0.97	1.20 ± 1.00	ns

Note: MAP, mean arterial blood pressure; ACE, angiotensin-converting enzyme; AT₁R, angiotensin-II type 1 receptor; ns, not significant.

Figure 2. Genotype distribution of aldosterone synthase (CYP11B2) gene C-344T polymorphism in group A (slow progressors) and group B (fast progressors) in n = 143 patients with biopsy-proven IgA nephropathy.

Note: *Chi square test.